Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company’s lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

34

Address:

Ayala Pharmaceuticals, Inc. 4 Oppenheimer Street Rehovot 7670104 Israel

Website:

Home

Phone:

972 8 373 1541

Leave a comment

Your email address will not be published. Required fields are marked *